ReviewFrontiers in oncology2020

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.

Leilei Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.